Fig. 3From: Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureOverall survival of patients ≥ 60 years of age with treated secondary AML by treatment approach and karyotype risk. (A) All patients, (B) adverse risk karyotype only, and (C) non-adverse risk karyotype onlyBack to article page